A systematic review of infliximab in the treatment of early rheumatoid arthritis

Figures & data

Table 1 Randomized trials of infliximab in early rheumatoid arthritis

		At study inclusion		Radiographic joint damage progression in 1 year		Secondary outcomes
First author	N	Disease duration	IFX dosage	vdH-S score (IFX group) (SD)	vdH-S score (MTX group) (SD)
St Clair et al 2004	1049	<3 years	IFX 3 mg/kg	0.4 (5.8)	3.7 (9.6)	ACR response; DAS 28;
(ASPIRE trial)			IFX 6 mg/Kg	0.5 (5.6)	3.7 (9.6)	HAQ; adverse effects
Goekoop-Ruiterman et al 2005 (<3 years BEST trial)	508	<3 years	IFX 3–6 mg/kg	−1.4 (4)	7.1 (−15.4)	HAQ score; adverse effects
Breedveld et al 2004 (ATTRACT sub-analysis)	66	<3 years	IFX 3 mg/kg	0.4 (−4.5)	9.1 (7.7)	vdH-Sharp score at 2 years follow up
Taylor et al 2004	24	<3 years	IFX 5 mg/Kg	3.3 (3.6)	12.2 (10.10)	US with power Doppler; CRP; Swollen joint count
Quinn et al 2005	20	<1 year				MRI scores at 1 year; ACR response; DAS 28; CRP; HAQ study
Smolen et al 2006 (ASPIRE trial)	1004	<3 years	IFX 3–6 mg/kg	a-	a-	Employability; ACR response; DAS 28;
Smolen et al 2006 (ASPIRE trial)	1004	<3 years	IFX 3–6 mg/kg	a-	a-	Correlation of CRP, ESR, and disease activity with RX progression
Taylor et al 2006	24	< 3 years	IFX 5 mg/Kg	a-	a-	Synovial thickness/color Doppler area/2 year therapy

a Duplicate data.

Abbreviations: ACR response, American College of Rheumatology response criteria; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Stanford Health Assessment Questionnaire; IFX, infliximab; MRI, magnetic resonance imaging; MTX, methotrexate.

St ClairEWvan der HeijdeDMSmolenJSCombination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trialArthritis Rheum20045034324315529377

 PubMed Web of Science ®Google Scholar

Goekoop-RuitermanYPde Vries-BouwstraJKAllaartCFClinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study):a randomized, controlled trialArthritis Rheum20055233819016258899

 PubMed Web of Science ®Google Scholar

BreedveldFCEmeryPKeystoneEInfliximab in active early rheumatoid arthritisAnn Rheum Dis2004631495514722203

 PubMed Web of Science ®Google Scholar

TaylorPCSteuerAGruberJComparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritisArthritis Rheum20045011071615077292

 PubMed Web of Science ®Google Scholar

QuinnMAConaghanPGO’ConnorPJVery early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal:results from a twelve-month randomized, double-blind, placebo-controlled trialArthritis Rheum200552273515641102

 PubMed Web of Science ®Google Scholar

SmolenJSHanCvan der HeijdeDInfliximab treatment maintains employability in patients with early rheumatoid arthritisArthritis Rheum2006547162216508932

 PubMed Web of Science ®Google Scholar

TaylorPCSteuerAGruberJUltrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritisArthritis Rheum200654475316385521

 PubMed Web of Science ®Google Scholar